Maze Therapeutics, Inc. MAZE · Stock Open Maze Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Maze Therapeutics, Inc. Analysis (MAZE)
Is Maze Therapeutics, Inc. a good investment? Maze Therapeutics, Inc. (MAZE) is currently trading at 33.38 USD. Market analysts have a consensus price target of 62.54 USD. This suggests a potential upside from current levels.
Earnings Schedule: Maze Therapeutics, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -3.19.
Investor FAQ
Does Maze Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.63.
Company Profile
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Community Discussion